Phaseline

Targets › H3F3A

H3F3A: drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Nov 2026.

Open in Phaseline: the race on H3F3A, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
German Cancer Research CenterH3K27M peptide vaccine
H3K27M neoepitope-specific peptide vaccine
H3F3APhase 1Newly Diagnosed H3-mutated GliomaNov 2026

Conditions

Newly Diagnosed H3-mutated Glioma (1)

Modalities

mixed (1)

Companies

German Cancer Research Center (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.